We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-2.89%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$935M
AUM Growth
+$227M
Cap. Flow
+$310M
Cap. Flow %
33.15%
Top 10 Hldgs %
70.78%
Holding
86
New
20
Increased
18
Reduced
12
Closed
29

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$32.9M
2
LLY icon
Eli Lilly
LLY
+$18.6M
3
FIVN icon
FIVE9
FIVN
+$11.3M
4
NICE icon
Nice
NICE
+$11.2M
5
META icon
Meta Platforms (Facebook)
META
+$9.65M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$26.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$16.3M
3
KYMR icon
Kymera Therapeutics
KYMR
+$15.6M
4
ZIM icon
ZIM Integrated Shipping Services
ZIM
+$10.8M
5
GNRC icon
Generac Holdings
GNRC
+$9.81M

Sector Composition

Rank Sector Weight
1 Healthcare 47.28%
2 Technology 3.05%
3 Communication Services 0.86%
4 Financials 0.27%
5 Consumer Discretionary 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OTMO
51
DELISTED
Otonomo Technologies Ltd. Ordinary shares
OTMO
$431K 0.05%
26,124
– –
ARBE icon
52
Arbe Robotics
ARBE
$80.3M
$237K 0.03%
43,165
– –
IMTXW
53
DELISTED
Immatics N.V. Warrants
IMTXW
$204K 0.02%
100,000
– –
VINC
54
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$93K 0.01%
3,523
-32,485
-90% -$1.44M
ABNB icon
55
CALL
Airbnb
ABNB
$89.9B
– –
-24,300
Closed -$4.17M
ALNY icon
56
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-24,768
Closed -$3.51M
ASND icon
57
Ascendis Pharma A/S
ASND
$16B
– –
-26,529
Closed -$3.11M
BMRN icon
58
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-211,326
Closed -$16.3M
CAT icon
59
Caterpillar
CAT
$375B
– –
-12,000
Closed -$2.67M
CSTE icon
60
Caesarstone
CSTE
$72.3M
– –
-428,046
Closed -$4.5M
BGMS
61
Bio Green Med Solution Inc
BGMS
$4.91M
– –
-141
Closed -$1.55M
FATE icon
62
Fate Therapeutics
FATE
$286M
– –
-89,425
Closed -$3.47M
FIVN icon
63
CALL
FIVE9
FIVN
$2.11B
– –
-248,900
Closed -$27.5M
IMUX icon
64
Immunic
IMUX
$190M
– –
-58,321
Closed -$6.59M
KRYS icon
65
Krystal Biotech
KRYS
$10.1B
– –
-25,310
Closed -$1.68M
KYMR icon
66
Kymera Therapeutics
KYMR
$8.51B
– –
-368,061
Closed -$15.6M
MA icon
67
Mastercard
MA
$502B
– –
-12,100
Closed -$4.32M
NAUT icon
68
Nautilus Biotechnolgy
NAUT
$124M
– –
-840,000
Closed -$3.65M
TEAD
69
Teads Holding Co
TEAD
$68.7M
– –
-52,531
Closed -$564K
PERI icon
70
Perion Network
PERI
$375M
– –
-306,051
Closed -$6.88M
PFE icon
71
Pfizer
PFE
$143B
– –
-515,070
Closed -$26.7M
QQQ icon
72
PUT
Invesco QQQ Trust
QQQ
$453B
– –
-126,000
Closed -$45.7M
REPL icon
73
Replimune Group
REPL
$941M
– –
-212,640
Closed -$3.61M
RUN icon
74
CALL
Sunrun
RUN
$2.34B
– –
-228,000
Closed -$6.92M
RUN icon
75
Sunrun
RUN
$2.34B
– –
-150,000
Closed -$4.56M
1 2
3
4

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2022 Portfolio in Review

As of Q2 2022, Sphera Funds Management held 86 positions worth $935M, up 32% from $708M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Sphera Funds Management deployed $310M of net new capital in Q2 2022, opening 20 new positions and adding to 18 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 437,748 shares worth $32.5M.

By sector, the portfolio is most concentrated in Healthcare at 47% of assets, down from 72% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Generac Holdings, an estimated $9.81M trimmed.

  • Sphera Funds Management's largest Q2 2022 buy was State Street SPDR S&P Biotech ETF: 437,748 shares worth $32.5M.
  • Sphera Funds Management added most to Eli Lilly in Q2 2022, an estimated $18.6M increase.
  • Sphera Funds Management's biggest Q2 2022 reduction was Generac Holdings, cutting an estimated $9.81M.
  • Sphera Funds Management fully exited Pfizer in Q2 2022, selling an estimated $26.7M.
  • Sphera Funds Management's ten largest holdings make up 71% of its $935M portfolio in Q2 2022.
  • Sphera Funds Management opened 20 new positions and closed 29 in Q2 2022.
  • Sphera Funds Management's portfolio value rose 32% quarter-over-quarter to $935M.

Based on Sphera Funds Management's 13F filing for Q2 2022, filed 15 Aug 2022.